CMS releases initial guidance on negotiating certain Medicare drug prices
The Centers for Medicare & Medicaid Services this week released for comment initial guidance implementing a program for Medicare to negotiate prices with drug makers for certain high-cost, single-source drug and biological products beginning in 2026 under the Inflation Reduction Act. The guidance details requirements and procedures for implementing negotiations in 2023 and 2024 for prices effective in 2026. CMS in January released a memo and timeline outlining how it will approach the program. According to the memo, the agency plans to actively engage hospitals and other stakeholders in the policymaking process.
Related News Articles
Headline
A new AHIP report makes baseless claims that hospitals drive up specialty drug costs when in fact insurance companies drive up profits by steering patients to…
Blog
A new AHIP “report” suggests that hospitals are significantly marking up the costs of drugs to the detriment of patients. They make baseless claims that…
Headline
About 84% of hospitals had posted a machine-readable file containing rate information by the end of first-quarter 2023, up from 65% the previous quarter,…
Headline
The Medicare Payment Advisory Commission today voted to recommend Congress adopt additional site-neutral payment policies for certain outpatient services;…
Headline
This April through June under the Inflation Reduction Act, Medicare will reduce the coinsurance amount for 27 Part B prescription drugs from 20% to somewhere…
Headline
Medicare should continue to pay average sales price plus 6% for most separately payable Part B drugs, but cap ASP inflation, AHA told the Medicare Payment…